Vaccine Irony: COVID Complicates Review, Uptake Of New RSV Vaccines
Executive Summary
COVID vaccines saved the world and then became a liability. US FDA vaccine advisors cited COVID experience as they urge agency to slow down on approval of new RSV vaccines, due to worries of declining public vaccine confidence and coadministration complications.
You may also be interested in...
US FDA Chief Scientist Thinks Increased Data Literacy Can Counter Misinformation
Chief Scientist Namandjé Bumpus wants FDA to do more to ensure the accessibility of scientific information, arguing empowering people to understand data themselves may help the US counter misinformation.
COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics
It took little convincing for FDA advisors to support changing COVID-19 vaccines to monovalent XBB formulations, but the committee still isn’t sold on the agency’s annual influenza-like campaign strategy for COVID vaccines and raised several harder calls that FDA and CDC will need to make including when to cut off bivalent shots use and who should get XBB.
GSK’s Walmsley On US v. EU COVID-Flu Combos, RSV Branding, And Investing In Infectious Disease
COVID vaccine makers already licensed in the US will have a leg up on in the combination respiratory vaccine space since aspiring new entrants like GSK will have to do efficacy work to get FDA approval. CEO Walmsley offers insight into the company’s vaccine strategy.